+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Necrotizing Fasciitis Market Forecast to 2033

  • PDF Icon

    Report

  • 100 Pages
  • October 2025
  • Region: Global
  • Grand View Research
  • ID: 6189485
REQUEST CUSTOMIZATION
Description Jump to:
The global necrotizing fasciitis market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 2.09 billion by 2033, growing at a CAGR of 8.3% from 2025 to 2033. The market is experiencing growth due to several key factors. Increasing awareness about the severity and rapid progression of the disease has led to a higher demand for effective treatments.

Advances in medical technology and the availability of innovative antibiotics and surgical interventions improve patient outcomes, further driving market expansion. Necrotizing Fasciitis (NF) is a serious skin and soft tissue infection that spreads along fascial planes with limited blood supply. It often leaves overlying tissues initially unaffected and delays diagnosis and treatment. As it progresses, it can involve fascia, peri-fascial planes, surrounding skin, soft tissue, and muscle. The condition affects around 0.4 per 100,000 people in the U.S. annually, with some areas reporting up to 1 per 100,000.

In addition,the rising prevalence of risk factors such as diabetes, obesity, and immunocompromised conditions is contributing to a greater number of cases. According to the International Diabetes Federation, diabetes was responsible for 3.4 million deaths in 2024, equivalent to one death every nine seconds, and 589 million adults (aged 20-79 years) are living with the condition worldwide. This rising diabetic population significantly increases the susceptibility to Necrotizing Fasciitis, fueling the demand for specialized care. Moreover, the growing focus of healthcare providers on early diagnosis and treatment, along with increased healthcare spending, is supporting the market's steady growth.

Global Necrotizing Fasciitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global necrotizing fasciitis market report based on type, treatment, distribution channel, and region:

Type Outlook (Revenue, USD Million, 2021-2033)

  • Type I (Polymicrobial)
  • Type II (Monomicrobial)
  • Type III (Gas gangrene / clostridial myonecrosis)

Treatment Outlook (Revenue, USD Million, 2021-2033)

  • Empiric broad-spectrum antibacterials
  • MRSA-coverage add-ons
  • Antitoxin adjunct for invasive GAS
  • Pathogen-targeted antibacterial regimens
  • Antifungals for necrotizing fungal infections
  • Immunotherapies

Distribution ChannelOutlook (Revenue, USD Million, 2021-2033)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • MEA

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Treatment
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Necrotizing Fasciitis Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
Chapter 4. Necrotizing Fasciitis Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2033
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021-2033 (USD Million)
4.4. Type I (Polymicrobial)
4.4.1. Type I (Polymicrobial) market estimates & forecasts, 2021-2033 (USD Million)
4.5. Type II (Monomicrobial)
4.5.1. Type II (Monomicrobial) market estimates & forecasts, 2021-2033 (USD Million)
4.6. Type III (Gas gangrene / clostridial myonecrosis)
4.6.1. Type III (Gas gangrene / clostridial myonecrosis) market estimates & forecasts, 2021-2033 (USD Million)
Chapter 5. Necrotizing Fasciitis Market: Treatment Business Analysis
5.1. Treatment Market Share, 2024 & 2033
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
5.4. Empiric broad-spectrum antibacterials
5.4.1. Empiric broad-spectrum antibacterials market estimates & forecasts, 2021-2033 (USD Million)
5.5. MRSA-coverage add-ons
5.5.1. MRSA-coverage add-ons market estimates & forecasts, 2021-2033 (USD Million)
5.6. Antitoxin adjunct for invasive GAS
5.6.1. Antitoxin adjunct for invasive GAS market estimates & forecasts, 2021-2033 (USD Million)
5.7. Pathogen-targeted antibacterial regimens
5.7.1. Pathogen-targeted antibacterial regimens market estimates & forecasts, 2021-2033 (USD Million)
5.8. Antifungals for necrotizing fungal infections
5.8.1. Antifungals for necrotizing fungal infections market estimates & forecasts, 2021-2033 (USD Million)
5.9. Immunotherapies
5.9.1. Immunotherapies market estimates & forecasts, 2021-2033 (USD Million)
Chapter 6. Necrotizing Fasciitis Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital pharmacies market estimates & forecasts, 2021-2033 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail pharmacies market estimates & forecasts, 2021-2033 (USD Million)
6.6. Online pharmacies
6.6.1. Online pharmacies market estimates & forecasts, 2021-2033 (USD Million)
Chapter 7. Necrotizing Fasciitis Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America necrotizing fasciitis market estimates & forecasts, by country, 2021-2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key country dynamics
7.4.2.2. Type disease prevalence
7.4.2.3. Regulatory framework
7.4.2.4. Reimbursement framework
7.4.2.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key country dynamics
7.4.3.2. Type disease prevalence
7.4.3.3. Regulatory framework
7.4.3.4. Reimbursement framework
7.4.3.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key country dynamics
7.4.4.2. Type disease prevalence
7.4.4.3. Regulatory framework
7.4.4.4. Reimbursement framework
7.4.4.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.5. Europe
7.5.1. Europe necrotizing fasciitis market estimates & forecasts, 2021-2033 (USD Million)
7.5.2. UK
7.5.2.1. Key country dynamics
7.5.2.2. Type disease prevalence
7.5.2.3. Regulatory framework
7.5.2.4. Reimbursement framework
7.5.2.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key country dynamics
7.5.3.2. Type disease prevalence
7.5.3.3. Regulatory framework
7.5.3.4. Reimbursement framework
7.5.3.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.5.4. France
7.5.4.1. Key country dynamics
7.5.4.2. Type disease prevalence
7.5.4.3. Regulatory framework
7.5.4.4. Reimbursement framework
7.5.4.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key country dynamics
7.5.5.2. Type disease prevalence
7.5.5.3. Regulatory framework
7.5.5.4. Reimbursement framework
7.5.5.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key country dynamics
7.5.6.2. Type disease prevalence
7.5.6.3. Regulatory framework
7.5.6.4. Reimbursement framework
7.5.6.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key country dynamics
7.5.7.2. Type disease prevalence
7.5.7.3. Regulatory framework
7.5.7.4. Reimbursement framework
7.5.7.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key country dynamics
7.5.8.2. Type disease prevalence
7.5.8.3. Regulatory framework
7.5.8.4. Reimbursement framework
7.5.8.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key country dynamics
7.5.9.2. Type disease prevalence
7.5.9.3. Regulatory framework
7.5.9.4. Reimbursement framework
7.5.9.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.6. Asia-Pacific
7.6.1. Asia-Pacific necrotizing fasciitis market estimates & forecasts, 2021-2033 (USD Million)
7.6.2. China
7.6.2.1. Key country dynamics
7.6.2.2. Type disease prevalence
7.6.2.3. Regulatory framework
7.6.2.4. Reimbursement framework
7.6.2.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.6.3. Japan
7.6.3.1. Key country dynamics
7.6.3.2. Type disease prevalence
7.6.3.3. Regulatory framework
7.6.3.4. Reimbursement framework
7.6.3.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.6.4. India
7.6.4.1. Key country dynamics
7.6.4.2. Type disease prevalence
7.6.4.3. Regulatory framework
7.6.4.4. Reimbursement framework
7.6.4.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key country dynamics
7.6.5.2. Type disease prevalence
7.6.5.3. Regulatory framework
7.6.5.4. Reimbursement framework
7.6.5.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key country dynamics
7.6.6.2. Type disease prevalence
7.6.6.3. Regulatory framework
7.6.6.4. Reimbursement framework
7.6.6.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key country dynamics
7.6.7.2. Type disease prevalence
7.6.7.3. Regulatory framework
7.6.7.4. Reimbursement framework
7.6.7.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.7. Latin America
7.7.1. Latin America necrotizing fasciitis market estimates & forecasts, 2021-2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key country dynamics
7.7.2.2. Type disease prevalence
7.7.2.3. Regulatory framework
7.7.2.4. Reimbursement framework
7.7.2.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key country dynamics
7.7.3.2. Type disease prevalence
7.7.3.3. Regulatory framework
7.7.3.4. Reimbursement framework
7.7.3.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa necrotizing fasciitis market estimates & forecasts, 2021-2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key country dynamics
7.8.2.2. Type disease prevalence
7.8.2.3. Regulatory framework
7.8.2.4. Reimbursement framework
7.8.2.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key country dynamics
7.8.3.2. Type disease prevalence
7.8.3.3. Regulatory framework
7.8.3.4. Reimbursement framework
7.8.3.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key country dynamics
7.8.4.2. Type disease prevalence
7.8.4.3. Regulatory framework
7.8.4.4. Reimbursement framework
7.8.4.5. Market estimates & forecasts, 2021-2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key country dynamics
7.8.5.2. Type disease prevalence
7.8.5.3. Regulatory framework
7.8.5.4. Reimbursement framework
7.8.5.5. Market estimates & forecasts, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Pfizer Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Merck & Co., Inc. (MSD)
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Gilead Sciences
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Astellas Pharma
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Basilea Pharmaceutica
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. CSL Behring
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Takeda
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Grifols
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Octapharma
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Hikma Pharmaceuticals
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Necrotizing Fasciitis Market, by Region, 2021-2033 (USD Million)
Table 4 Global Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 5 Global Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 6 Global Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 7 North America Necrotizing Fasciitis Market, by Country, 2021-2033 (USD Million)
Table 8 North America Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 9 North America Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 10 North America Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 11 U.S. Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 12 U.S. Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 13 U.S. Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 14 Canada Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 15 Canada Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 16 Canada Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 17 Mexico Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 18 Mexico Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 19 Mexico Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 20 Europe Necrotizing Fasciitis Market, by Country, 2021-2033 (USD Million)
Table 21 Europe Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 22 Europe Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 23 Europe Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 24 UK Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 25 UK Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 26 UK Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 27 Germany Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 28 Germany Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 29 Germany Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 30 France Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 31 France Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 32 France Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 33 Italy Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 34 Italy Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 35 Italy Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 36 Spain Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 37 Spain Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 38 Spain Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 39 Denmark Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 40 Denmark Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 41 Denmark Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 42 Sweden Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 43 Sweden Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 44 Sweden Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 45 Norway Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 46 Norway Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 47 Norway Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 48 Asia-Pacific Necrotizing Fasciitis Market, by Country, 2021-2033 (USD Million)
Table 49 Asia-Pacific Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 50 Asia-Pacific Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 51 Asia-Pacific Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 52 Japan Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 53 Japan Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 54 Japan Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 55 China Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 56 China Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 57 China Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 58 India Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 59 India Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 60 India Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 61 Australia Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 62 Australia Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 63 Australia Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 64 South Korea Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 65 South Korea Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 66 South Korea Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 67 Thailand Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 68 Thailand Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 69 Thailand Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 70 Latin America Necrotizing Fasciitis Market, by Country, 2021-2033 (USD Million)
Table 71 Latin America Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 72 Latin America Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 73 Latin America Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 74 Brazil Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 75 Brazil Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 76 Brazil Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 77 Argentina Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 78 Argentina Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 79 Argentina Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 80 Middle East & Africa Necrotizing Fasciitis Market, by Country, 2021-2033 (USD Million)
Table 81 Middle East & Africa Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 82 Middle East & Africa Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 83 Middle East & Africa Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 84 South Africa Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 85 South Africa Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 86 South Africa Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 87 Saudi Arabia Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 88 Saudi Arabia Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 89 Saudi Arabia Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 90 UAE Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 91 UAE Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 92 UAE Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
Table 93 Kuwait Necrotizing Fasciitis Market, by Type, 2021-2033 (USD Million)
Table 94 Kuwait Necrotizing Fasciitis Market, by Treatment, 2021-2033 (USD Million)
Table 95 Kuwait Necrotizing Fasciitis Market, by Distribution Channel, 2021-2033 (USD Million)
List of Figures
Figure 1 Necrotizing fasciitis market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and disease outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Necrotizing fasciitis market dynamics
Figure 12 Necrotizing fasciitis market: Porter’s five forces analysis
Figure 13 Necrotizing fasciitis market: PESTLE analysis
Figure 14 Type market, 2021-2033 (USD Million)
Figure 15 Type I (Polymicrobial) market, 2021-2033 (USD Million)
Figure 16 Type II (Monomicrobial) market, 2021-2033 (USD Million)
Figure 17 Type III (Gas gangrene / clostridial myonecrosis) market, 2021-2033 (USD Million)
Figure 18 Treatment market, 2021-2033 (USD Million)
Figure 19 Empiric broad-spectrum antibacterials market, 2021-2033 (USD Million)
Figure 20 MRSA-coverage add-ons market, 2021-2033 (USD Million)
Figure 21 Pathogen-targeted antibacterial regimens market, 2021-2033 (USD Million)
Figure 22 Antifungals for necrotizing fungal infections market, 2021-2033 (USD Million)
Figure 23 Immunotherapies market, 2021-2033 (USD Million)
Figure 24 Distribution channel market, 2021-2033 (USD Million)
Figure 25 Hospital pharmacies market, 2021-2033 (USD Million)
Figure 26 Retail pharmacies market, 2021-2033 (USD Million)
Figure 27 Online pharmacies market, 2021-2033 (USD Million)
Figure 28 Necrotizing fasciitis market revenue, by region
Figure 29 Regional marketplace: Key takeaways
Figure 30 North America necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 31 U.S. country dynamics
Figure 32 U.S. necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 33 Canada country dynamics
Figure 34 Canada necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 35 Mexico country dynamics
Figure 36 Mexico necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 37 Europe necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 38 UK country dynamics
Figure 39 UK necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 40 Germany country dynamics
Figure 41 Germany necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 42 France country dynamics
Figure 43 France necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 44 Italy country dynamics
Figure 45 Italy necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 46 Spain country dynamics
Figure 47 Spain necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 48 Denmark country dynamics
Figure 49 Denmark necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 50 Sweden country dynamics
Figure 51 Sweden necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 52 Asia-Pacific Necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 53 China country dynamics
Figure 54 China necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 55 Japan country dynamics
Figure 56 Japan necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 57 India country dynamics
Figure 58 India necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 59 Australia country dynamics
Figure 60 Australia necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 61 South Korea country dynamics
Figure 62 South Korea necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 63 Thailand country dynamics
Figure 64 Thailand necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 65 Latin America Necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 66 Brazil country dynamics
Figure 67 Brazil necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 68 Argentina country dynamics
Figure 69 Argentina necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 70 MEA Necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 71 South Africa country dynamics
Figure 72 South Africa necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 73 Saudi Arabia country dynamics
Figure 74 Saudi Arabia necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 75 UAE country dynamics
Figure 76 UAE necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 77 Kuwait country dynamics
Figure 78 Kuwait necrotizing fasciitis market, 2021-2033 (USD Million)
Figure 79 Company categorization
Figure 80 Company market position analysis
Figure 81 Strategic framework

Companies Mentioned

The companies profiled in this Necrotizing Fasciitis market report include:
  • Pfizer
  • Merck & Co. (MSD)
  • Gilead Sciences
  • Astellas Pharma
  • Basilea Pharmaceutica
  • Takeda
  • CSL Behring
  • Grifols
  • Octapharma
  • Hikma Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages100
PublishedOctober 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 1.02 Billion
Forecasted Market Value ( USD ) by 2033 $ 2.09 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Reports

Necrotizing Fasciitis Treatment Market - Global Forecast 2025-2030 - Product Image

Necrotizing Fasciitis Treatment Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Plantar Fasciitis Treatment Market Forecast to 2033 - Product Image

Plantar Fasciitis Treatment Market Forecast to 2033

  • Report
  • 150 Pages
  • Global
From
Skin Grafting Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Skin Grafting Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Diagnostic Pathology: Nonneoplastic Pediatrics. Edition No. 2 - Product Image

Diagnostic Pathology: Nonneoplastic Pediatrics. Edition No. 2

  • Book
Diagnostic Pathology: Intraoperative Consultation. Edition No. 3 - Product Image

Diagnostic Pathology: Intraoperative Consultation. Edition No. 3

  • Book
Copyright © 2002-2025 Research and Markets. All Rights Reserved.